Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

1(25.0%)

Phase 4

1(25.0%)

N/A

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 3(1)

Phase 4(1)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT02022930Phase 3Completed

Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis

Role: lead

NCT01134406Phase 2Completed

Hydros Joint Therapy and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis (OA)

Role: lead

NCT00665574Not ApplicableTerminated

ActaVisc and ActaVisc Mx Intra-articular Injection for Pain Associated With Osteoarthritis in the Knee

Role: lead

NCT00554190Phase 4Completed

Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel

Role: lead

All 4 trials loaded